Trial Profile

A Randomised, Double-blind, Placebo-controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 13 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Jul 2022 According to a Savara Pharmaceuticals media release, data from the study will be presented at the European Respiratory Society (ERS) International Congress 2022. The full content of the abstract will be available in the Congress's online program and will be published in a supplement of the European Respiratory Journal (ERJ) by the end of November 2022.
08 Sep 2020 Results presented in a Savara Pharmaceuticals media release.
08 Sep 2020 According to a Savara Pharmaceuticals media release, results from the this study were published online in New England Journal of Medicine.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com